We saw a mix of funding and acquisition news for New England’s tech and life sciences startups this week.
—Carbonite, a Boston-based online data backup firm, revealed it was planning to go public. The company, which has raised more than $67 million in venture capital, didn’t yet say how many shares it will be offering or how much it will be pricing them at, but it aims to trade on the Nasdaq under the ticker symbol CARB.
—Waltham, MA-based Augmenix nabbed a $15 million equity investment from Varian Medical Systems of Palo Alto, CA, giving the latter firm a minority stake in Augmenix, a developer of radiation technology for treating cancer patients. Varian (NYSE: [[ticker:VAR]]) is also getting an exclusive option to acquire Augmenix if certain milestones are met.
—MoMelan Technologies, a Cambridge, MA-based maker of a device to treat skin disorders by expanding the surface area of skin grafts, brought in $3.5 million in funding. It added KLP Enterprises and Life Science Angels to its existing list of investors, which includes LaunchCapital and Mass Medical Angels.
—Cambridge-based Typesafe, an IT startup focused on the Scala programming language, raised $3 million in a Series A financing led by Greylock Partners. The deal also included individual investors hailing from firms such as Facebook, VMWare, Oracle, and Google.
—Massachusetts tech and life sciences startups inked $306 million in investments in April, according to data provided by CB Insights. A $77 million Series G financing for Merrimack Pharmaceuticals of Cambridge helped plump up that total.
—Boston-based data management and protection company Iron Mountain (NYSE: [[ticker:IRM]]) said it is selling three of its businesses for a total of $380 million to Autonomy, based in the U.K. and San Francisco. The company is shedding its online backup and recovery, digital archiving, and eDiscovery units.
—PerkinElmer, the Waltham, MA-based provider of life sciences products, bought Ontario-based Labtronics, a provider of electronic notebook technology for laboratory analysis. Terms of the deal weren’t disclosed.
—Boston-based SciFluor Life Sciences, a maker of technology for enhancing drugs and commercial chemicals with fluorine, snapped up $5 million in funding from Allied Minds.
